Clinical trials: LTBI
Latent Tuberculosis
Clinical Practice Guidelines Versus Decision-support for Latent Tuberculosis Infection (LTBI) Management
Latent Tuberculosis infection (LTBI) guidelines can be complex. LTBI-ASSIST is a web-based interactive tool to navigate US LTBI clinical practice guidelines in a patient-centered format that may guide clinical decision making…
- Trial name
- NCT05772065
- Testing
- CDC/NTCA guidelines only, LTBI ASSIST and CDC/NTCA guidelines only
- Where
- United States
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Tuberculosis
Latent Tuberculosis in Healthcare Workers - the Reality of a Portuguese Tertiary Hospital
Prospective, descriptive study to assess latent tuberculosis infection (LTBI) among healthcare worker (HCW) in a tertiary hospital in a low-risk area.
- Trial name
- NCT05847491
- Testing
- IGRA/Tuberculin skin test
- Where
- Portugal
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Centro Hospitalar do Oeste
Tuberculosis
Safety and Risk of Sensitisation of the rdESAT-6 + rCFP-10 Skin Test Following Repeated Intradermal Administration
The primary objective is to assess the safety of three dose levels (0.01, 0.1 and 1.0 µg) of the rdESAT-6 + rCFP-10 skin test reagent when injected into healthy adults.
- Trial name
- NCT00793702
- Testing
- rdESAT-6 + rCFP-10
- Where
- Denmark
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Statens Serum Institut
Tuberculosis (TB), Tuberculosis Infection, Latent
Burden of Tuberculosis Among Pregnant and Postpartum Women in Guinea-Bissau
This study aims to address critical diagnostic and data gaps in tuberculosis (TB) care among pregnant and postpartum women in Guinea-Bissau, a high-burden, resource-limited setting.
- Conditions
- Tuberculosis (TB), Tuberculosis Infection, Latent, Pregnancy, Tuberculosis Diagnosis
- Trial name
- TIPP (NCT07419568)
- Testing
- Enhanced protocol
- Where
- Guinea-Bissau
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Aarhus University Hospital
Tuberculosis
A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 (C-011-404)
This Phase I study will be conducted as a randomized, placebo-controlled, double-blind, dose-escalation study in four groups of healthy adult male and female subjects who are BCG-vaccinated, HIV-negative, and have no evidence of…
- Trial name
- C-011-404 (NCT02109874)
- Testing
- AERAS-404 (mcg H4/nmol IC31), Sterile buffer containing 10 mmol/L tris and 169 mmol/L NaCl
- Where
- South Africa
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Aeras
Active Tuberculosis
Characterization and Evaluation of Diagnostic Biomarkers for Tuberculosis
There was no sensitive and specific biomarker for tuberculosis infection, disease progression and predicting the prognosis of treatment.
- Trial name
- NCT01269268
- Where
- South Korea
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Tuberculosis
Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis (TB) in Elderly Residents of Nursing Homes?
In face of the increased rates of tuberculosis in residents of long term care facilities, annual screening for latent tuberculosis is recommended.
- Trial name
- NCT00756808
- Where
- United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Tuberculosis, Latent Tuberculosis Infection
VDOT for Monitoring Adherence to LTBI Treatment
The three-month short-course treatment with isoniazid [H] and rifapentine [P] (3HP) recently recommended by the Centers for Disease Control and Prevention could dramatically increase the number of persons starting and completing…
- Trial name
- VMALT (NCT02641106)
- Testing
- Video Directly Observed Therapy, In-Person DOT
- Where
- United States
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Compliance, Patient
Treatment of Latent Tuberculosis in Socially Marginalised Citizens
An open-label, randomised controlled trial comparing compliance to treatment for latent tuberculosis infection in socially marginalised citizens.
- Trial name
- DOT-LTBI (NCT03266991)
- Testing
- Rifapentine, Isoniazid
- Where
- 2 sites in Denmark
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Aarhus University Hospital
Close Contacts of Active Tuberculosis
Efficacy of Nyaditum Resae(R) Against Active TB in Georgia
The use of a supplement food like "Nyaditum resae" is a reliable opportunity to stop the progression towards active TB through the most updated knowledge of this disease:the induction of tolerance.
- Trial name
- NCT02897180
- Testing
- Nyaditum resae(R)
- Where
- Georgia
- Volunteers
- 3,300 people, healthy volunteers welcome
- Sponsor
- Fundació Institut Germans Trias i Pujol
Latent Tuberculosis Infection (LTBI)
C-TST for Diagnosis of Latent Mycobacterium Tuberculosis Infection in Indonesia
This is an operational research in household/close contacts of confirmed TB patients to evaluate the effectiveness of C-TST compared to IGRA test in identifying latent TB cases using parameters of effectiveness and safety.
- Trial name
- C-TST (NCT07587164)
- Testing
- Recombinant Mycobacterium Tuberculosis Fusion Protein Tuberculin Skin Test (C-TST)
- Where
- Indonesia
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Tuberculosis, Psoriasis
Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Patients With Psoriasis
The purpose of this study is to determine the level of agreement between QuantiFeron -TB Gold test (QFT-G)and Tubeculin skin test (TST)for screening of latent tuberculosis in patients suffering from psoriasis.
- Trial name
- NCT01223976
- Testing
- Tuberculin skin test and Quantiferon -TB Gold test
- Where
- Israel
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Tuberculosis Infection
Dose Study of Tuberculin Purified Protein Derivative (JHP/Dose)
Dose comparison study of tuberculin purified protein derivative (PPD)Aplisol with the standard tuberculin purified derivative (PPD-S2).
- Trial name
- NCT01689831
- Testing
- To confirm the potency of Aplisol formulated with newly produced Tuberculin PPD compared to PPD-S2 standard., Reactivity of Aplisol compared to reference standard PPD-S2.
- Where
- United States
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- JHP Pharmaceuticals LLC
Tuberculosis Infection
Safety and Tolerability of Chlorquine in Addition to Anti-tuberculosis Therapy
In vitro and in vivo data show promising results of adjunctive use of Chloroquine to standard tuberculosis therapy as Chloroquine enhances animicrobial effectiveness against intracellular MTB.
- Trial name
- NCT05443178
- Testing
- Nivaquine ® (Chloroquine)
- Where
- Switzerland
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Tuberculosis, Tuberculosis (TB)
Shaping a Community-based Pathway to Improve TB Surveillance Among African and Hindustan Immigrants Experiencing Vulnerabilities
This two-phase, mixed-methods approach project aims to develop a community-based, participatory, and co-created TB/TB infection (TBI) screening care pathway for African and Hindustan immigrants, who often face socioeconomic…
- Conditions
- Tuberculosis, Tuberculosis (TB), Tuberculosis Active, Tuberculosis Infection, Latent
- Trial name
- AFROHINDU-MIGT (NCT07687121)
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Universidade Nova de Lisboa
Tuberculosis Infection
Evaluation of ТВ/Flu-05Е Vaccine for the Prevention of Tuberculosis Infection in BCG-vaccinated Volunteers Aged 18-50 Years
The aim of the study is to investigate safety, reactogenicity and immunogenicity of the TB/Flu-05E single-dose intranasal vaccine for the prevention of Tuberculosis infection in BCG-vaccinated Volunteers aged 18-50 years.
- Trial name
- NCT05945498
- Testing
- TB/Flu-05E vaccine
- Where
- Russia
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Tatyana Zubkova
Latent Tuberculosis, Latent Tuberculosis Bacteriology and Histology Unknown
Safety and Immunogenicity Study of AERAS-456 Vaccine for Tuberculosis
This is a Phase I, open-label, dose-escalation study with three study groups. This study will be conducted in 25 HIV negative subjects, 17 of whom will have Latent Tuberculosis Infection (LTBI) and 8 of whom will not have LTBI at…
- Trial name
- NCT01967134
- Testing
- H56:IC31
- Where
- South Africa
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Aeras
Latent Tuberculosis Infection
Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein
Cohort 1 was a randomized, double-blind, controlled clinical trial with a planned enrollment of 500 patients. Cohort 2 is a non-randomized, open-label clinical trial with a planned enrollment of approximately 60000 patients.
- Trial name
- NCT05746611
- Testing
- Recombinant Mycobacterium tuberculosis fusion protein for injection, TB-PPD was injected
- Where
- China
- Volunteers
- 7,500 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
HIV Infection, Tuberculosis
Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV
Tuberculosis (TB) is highly endemic in sub-Saharan Africa. The increased burden of TB in settings with high prevalence of the Human Immunodeficiency Virus (HIV) is associated with high rates of transmission of Mycobacterium…
- Conditions
- HIV Infection, Tuberculosis, Pneumocystis Jiroveci Pneumonia
- Trial name
- NCT00080119
- Testing
- Isoniazid (INH), Trimethoprim/Sulfamethoxazole (TMP/SMX)
- Where
- 6 sites in Botswana, South Africa
- Volunteers
- 1,354 people, healthy volunteers welcome
- Sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Tuberculosis Infection
Evaluation of Immune Cell Markers in Diagnosis of Tuberculosis
Diagnosis of active and latent pulmonary tuberculosis, as well as extrapulmonary tuberculosis, is still a major challenge of TB control in China.
- Trial name
- NCT04148053
- Testing
- TB-antigen responsive T cell markers
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tongji University